Pacira Pharmaceuticals Inc. is recalling 43,768 kits of Zilretta (triamcinolone acetonide extended-release injectable suspension), 32 mg per vial. The recall was issued because the medication failed stability testing requirements during long-term refrigerated storage. Zilretta is a prescription injectable medication used to treat osteoarthritis pain in the knee.
A failure in stability testing means the medication may not maintain its intended strength or quality over time. Using an unstable drug can lead to reduced treatment effectiveness or unexpected side effects.
Quantity affected: 43,768 kits. Kit includes Drug Vial and Diluent Vial.
If you or a family member were harmed by this recalled product, you may have legal rights. Consider consulting a consumer protection attorney to understand your options for compensation.
This is general information, not legal advice. Go Backs is not a law firm and does not provide legal services.
AI-Enhanced Content: The summary, action steps, and risk assessment on this page were generated by AI from official government recall data to improve readability. This is not legal or medical advice. Always refer to the official agency sources below for authoritative information.
Sources: FDA iRES · Raw API Response
openFDA Disclaimer: This recall information is sourced from the openFDA API. Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. Refer to the openFDA terms of service for more information.